Class actions hold our interest, even though we do not see them all that often anymore in the drug and medical device space. Maybe we are the rubbernecking motorists who can’t resist slowing down to gaze at someone else’s fender bender. Maybe we are the children at the zoo who rush to the reptile house
February 2018
Off-Label Marketing MDL Winds Down With Some Summary Judgment
We have written extensively on the travesty of the Neurontin trilogy (like here and here) and noted how the plaintiffs’ efforts to fit cases based on alleged off-label promotion of the prescription SSRIs Celexa and Lexapro into the same rubric have not been as successful. Today’s case addresses what we understand to be some…
E.D. Wash. Rejects Successor Liability in Hip Implant Case
Our first stint in a law firm was on the transactional side. Yes, it sounds crazy even to us, but we spent our first 18 months in the profession pulling all-nighters on triple-tier financings of leveraged buyouts, doing clueless due diligence in far-flung back-offices, drafting trust indentures, ‘slugging’ at the printers, and collecting acrylic cubes …
Only You Can Prevent….
We’ve seen the latest affirmance of largely identical verdicts in a consolidated MDL trial in Campbell v. Boston Scientific Corp., ___ F.3d ___, 2018 WL 732371 (4th Cir. Feb. 6, 2018). We’re not discussing Campbell’s merits today. For present purposes, suffice it to say that the consolidation- and punitive damages-related rulings aren’t that…
Guest Post – The Federal Judicial Center’s Mandatory Initial Discovery Pilot Project Complicates Litigation In Adopting Districts
Today’s guest post is by Reed Smith‘s Lisa Baird, who has written about her recent experience with mandatory initial discovery, as practiced in a “Pilot Project” in place in certain federal district courts. It was interesting – in the “stop and think before you remove to federal court” sense of interesting. As always…
Guest Post – Illinois Court Rejects Novel Claims Alleging Deficiencies In Post-Approval Studies
Today we have a guest post from Reed Smith‘s Elizabeth Minerd discussing a PMA preemption case dealing with unusual “parallel claim” allegations involving the conduct of clinical trials. As always our guest posters are 100% responsible for what they write and deserve 100% of the credit (and any blame) for what follows. Take it…
Federal Court Certifies Question to Utah Supreme Court of Whether Comment K Applies to Medical Devices
Strict liability is not the same as absolute liability. We learned that truth in law school, but too many plaintiff lawyers and judges seem to have unlearned it along the way. The key separator between strict liability and absolute liability is comment k to section 402A of the Restatement (Second) of Torts (1965), which observes …
Long Overdue Generic Dismissal
The Lawyer Full Employment Action of 2018
On January 30, 2018, Judge Goodwin entered four case management orders in the Ethicon, Boston Scientific, Bard, and American Medical Systems mesh MDLS. These CMOs establish discovery and briefing deadlines for 13200, 6174, 2876, and 952, cases respectively – a total of 23202 cases.
The discovery and briefing schedules are identical in…
Eleventh Circuit Affirms Summary Judgment for Defendants in Enbrel Case
This year’s Academy Award nominations came out last week. That means that we have spent the past few days setting a schedule for seeing all of the Best Picture nominees (well, most – we don’t do war movies and tend to opt out of love stories involving semi-animate objects) and scouring recipe blogs for perfect…